INTRODUCTION
The effect of the carbonic anhydrase (EC 4.2.1.1) inhibitor, acetazolamide (Diamox), on cerebral blood flow (CBF)1 has been studied by many investigators Received for publicationi 29 July 1977 atid itn revised form 21 April 1978.
'Abbreviatiotis used in this paper: a-v, arterio-venous; CBF, cerebral blood flow; CMRO2, cerebral metabolic rate for oxygen.
(1-7). All report that that intravenous administration of acetazolamide significantly increases CBF without affecting the cerebral metabolic rate for oxygen (CMRO2). This reported increase in CBF cannot be entirely explained by the known hypercapnic effect of acetazolamide because the increase in CBF is not eliminated by controlling the arterial carbon dioxide tension. The results of these investigators are summarized in Table I .
We have reexamined the effect of acetazolamide on CBF and although we observed an increase, it was consistently less than the large increases in CBF others have reported (1) (2) (3) (4) (5) (6) (7) . This apparent discrepancy prompted us to measure the effect of acetazolamide on the CMRO2 because the reported CBF changes after intravenous acetazolamide (Table I) are based, in large measure, on the use of the brain arteriovenous oxygen difference as an index of CBF. Such an approach to the measurement of CBF makes the important assumption that CMRO2 remains constant (8) . The evidence that the CMRO2 is unaffected by intravenous acetazolamide is based on a single report (4) . We observed a significant decrease in CMRO2 minutes after intravenous acetazolamide. This decrease in CMRO2, coupled with the modest but significant increase in CBF, we observe, is sufficient to explain most previous claims of a large increase in CBF estimated from brain arteriovenous oxygen differences. Further and more important, this observation suggests that the brain may be dependent to a greater extent than previously realized on erythrocyte carbonic anhydrase for adequate tissue oxygenation.
METHODS
Materials. Acetazolamide was obtained as Diamox from Lederle Laboratories, Div. of American Cyanamid Co., Pearl River, N. Y. The '5O-labeled H2O and 150-labeled 02 used in these studies were prepared with the Washington University cyclotron according to procedures previously reported (9) . Experimenital procedure. All the studies were performed on adult rhesus monkeys (Macaca mulatta). carotid artery as a small bolus (0.25 ml) of the animal's blood labeled with one or the other radiopharmaceutical. To assure that the radioisotopes entered only the internal carotid artery, the right external carotid artery was ligated at the bifurcation ofthe common carotid artery at least 2 wk before experimentation. The effect of such a surgical procedure on our experimental results is considered to be negligible. This matter has been dealt with in detail elsewhere (10) . For each experiment, the monkeys were anesthetized with phencyclidine (3 mg/kg Sernylan, Bio-Ceutic Laboratories, Inc., St. Joseph, Mo.), paralyzed with gallamine triethiodide /Flaxidyl, Davis-Geck, American Cyanamid Co., Pearl River, N. Y.), intubated with a cuffed endotracheal tube, and passively ventilated with an animal respirator (Harvard Apparatus Co., Inc., Millis, Mass.) on 100% oxygen. Gas mixtures of 5% C02-95% 02 or 10% C02-90% 02 were used in some experiments to establish control Paco2's at higher levels. At least 20 min was allowed for the monkeys to stabilize on the new gas mixture before any measurements were made. A 1.4-mm outside diameter catheter was inserted in the femoral artery, with its tip positioned in the right carotid artery under fluoroscopic guidance. To prevent clotting in this catheter system, which was used for the injection of radiopharmaceuticals, monitoring arterial blood pressure, and sampling arterial blood, all animals were anticoagulated with heparin at the beginning ofthe experiment. Arterial blood pressure, end-tidal Pco2, and rectal temperature were continuously monitored. Body temperature was kept around 37°C with a heating pad. Arterial Pco2, pH, Po2, oxygen saturation, hematocrit, hemoglobin, and oxygen content were measured either shortly before or after each radiopharmaceutical injection. All blood gas samples were drawn in previously heparinized l-ml plastic syringes with the dead space filled with heparin. All blood gas data presented in this report were corrected for temperature deviations. Corrections for heparin dilution were unnecessary because the maximum dilution was 1:24. Corrections to the Po2 data for the "stirring effect" were unnecessary because the calibrating samples were subject to the same error.
CBF was determined by the injection of [150]H2O (11 (12, 13) . The sequence was as follows: an aliquot of 0'50-labeled blood was injected into the carotid artery; after allowing 35 s to follow the washout, an arterial blood gas sample was drawn. Typically, within 2-3 min of the [P5002 injection, the radioactive background from the first injection was down to an acceptable level for the injection of the aliquot of [P530H20-labeled blood. All determinations of CMRO2 were run at Paco2 levels in the range of 40-50 torr. As with the CBF alone, three or four control injection pairs were made before the administration of 30 mg/kg of acetazolamide, and four or five more paired injections afterward. The blood used for [150]02 injections after acetazolamide administration also contained acetazolamide. This blood was obtained from the monkey after the drug had been administered. Thus, concentration of drug in the injected bolus was equal to that in the monkey.
Because carbonic anhydrase is carried in erythrocytes and not plasma, we thought it appropriate to qualitatively determine the effect of this partitioning on oxygen delivery to the brain. This question was approached by a triple injection procedure in three experiments run on two monkeys. Two of the injections were [550JH20-and [550]02-labeled normal monkey blood. The third injection was [150102-labeled blood that had been hemolyzed before labeling. In the first experiment, osmotic hemolysis was used; in the second and third, an ultrasonic probe (Artek Systems Corp., Farmingdale, N. Y.) was used to lyse the cells. All three injections were carried out within a 5-min period. As usual, three or four such injection sequences were done before drug administration and four or five after drug administration. Acetazolamide-containing blood, both normal and hemolyzed, was used for all [150102 injections after acetazolamide had been given to the monkey.
To assure ourselves that the brain oxygen extraction and, hence, CMRO2 measured by the oxygen-15 technique accurately reflected changes actually occurring under the peculiar circumstances of this experiment, we made a direct comparison of oxygen-15 extraction and the measured arteriovenous (a-v) difference in two studies. This was done in two monkeys that had specially designed Teflon (E. I. DuPont de Nemours & Co., Wilmington, Del.) appliances (E. Koegel, San Antonio, Tex.) placed posteriorly in the calvaria over the superior sagittal sinus which allowed easy, repetitive sampling of mixed cerebral venous blood, and hence, direct determination of brain arteriovenous oxygen difference. We have found an excellent correlation between oxygen content of blood taken with this appliance from this site and jugular bulb oxygen content in the rhesus monkey, directly supporting the contention that this represents cerebralmixed venous blood. 2 Monkeys used for more than one experiment were allowed to recuperate for a minimum of 2 wk between procedures. Radioisotope detectiotn and data collection. The washout of the radioisotopes was followed with a single 3 x 2 inch Nal (Tl) scintillation detector collimated and placed to assure uniform detection ofthe right cerebral hemisphere. The signal from the detector was fed into a LINC laboratory minicomputer (Digital Equipment Corp., Maynard, Mass.) for data storage and analysis.
Data analysis. The details of the data analysis are completely described elsewhere (10-13) and will not be repeated here. In general, each injection of a labeled compound allows us to compute the extraction fraction of that compound, i.e., that percentage of the compound which is extracted from the injection bolus on a single pass through the brain. In addition, the rate of washout of [150]H20 allows computation of CBF in milliliters per minute per 100 g tissue (11) . The cerebral metabolic rate for oxygen is given by the extraction fraction of oxygen times cerebral blood flow times arterial oxygen content. Experimental justification for these methods has been previously published (11) (12) (13) .
RESULTS
Effect of acetazolarnide on CBF. 22 experiments were performed on 12 monkeys. 2 experiments were rejected. In both cases there was no net increase in CBF after acetazolamide administration, even though there was a significant increase in PaCo2. Furthermore, considering the PacO2 levels, baseline CBF was depressed in these animals, suggesting that the normal reactivity of the cerebral vasculature was impaired in these animals. Thus, there are 79 control and 97 experimental data points (Fig. 1) . Fig. 1 shows the relationship between CBF and Paco2 for the control (predrug) and experimental populations. Control Paco2 was varied over the range shown by mild hypo-or hyperventilation and (or) ventilation with gas mixtures containing 5 or 10% carbon dioxide balanced with oxygen. The equations for the regression lines and 95% confidence intervals of the slopes and intercepts 2 Raichle, M. E. Unpublished observations. FIGURE 2 The change in miiean CBF anid meani Paco2 after intravenious admiinlistrationi of acetazolamide in rhesus miionikeys. The The resulting a-v oxygen difference is 56.5% of control, which is a significant difference (P < 0.00001). Using this as an indicator of a change in CBF, as several investigators have done (see Table I ), would imply a 77% increase in CBF (1/0.565 = 177%), assuming that there was no change in the CMRO2 and remembering that Paco2 was uncontrolled. It is clear from our data, however, that CMRO2 changed.
Effect of acetazolamide on CMR02. 12 experiments run on 8 monkeys resulted in 45 control data points and 24 experimental data points. The data are presented in Fig. 4 . The mean control CMRO2 before normalization was 4.16 ml/min per 100 g. After acetazolamide, the CMRO2 dropped to 67.8% of control. A paired t test shows this decrease to be significant (P < 0.00001).
Effect of hemolysis on CMRO2. To determine the effect of confinement of carbonic anhydrase to the erythrocyte in circulating blood on oxygen delivery to the brain, we performed three additional experiments on two monkeys. The results are shown in Fig. 5 . A paired t test shows that there was a significant difference between the control CMRO2 obtained with normal blood and the control CMRO2 obtained with hemolyzed blood (4.14 and 4.50 ml/min per 100 g, respectively, P < 0.0067). However, there was no significant difference between the mean CMRO2's obtained after acetazolamide with normal and hemolyzed blood (2.99 and 2.96 ml/min per 100 g, respectively, P > 0.33). The overall drop in CMRO2 is of course similar to that obtained in the preceding nine experiments (Fig. 4) . DISCUSSION Our data show that the intravenous administration of acetazolamide sufficient to acutely inhibit all circulat- 4 The effect of intravenous administration acetazolamide on CMRO2. The mean control CMRO2 was 4.16 ml/min per 100 g. FIGURE 5 The effect of hemolysis of the oxygen-15-labelecl blood used to measure the CMRO2 before (control) and after the intravenous administration of acetazolamide to rhesus monkeys. The mean control CMRO2 obtained with nonhemolyzed blood was 4.14 ml/min per 100 g.
ing carbonic anhydrase increases CBF 29.2%. This increase in CBF is accompanied by a significant increase in arterial carbon dioxide tension. This increase in Paco2 is well known to occur with acetazolamide because of the effect of this drug on slowing the conversion of HCO3 to diffusible CO2 in the lung capillaries (14) . The most obvious indication of this during our experiments was an immediate fall in end-tidal Pco2 to -50% of normal after acetazolamide administration. Both our work and that of others (Table I, [1] [2] [3] suggest the acetazolamide-induced hypercapnia is only partly responsible for the increase in CBF observed. Statistical correction of our CBF data for the Paco2 increase reduces the observed CBF increase from 29.2 to 15.4%. We may well be overestimating the effect of Paco2 in our data due to the difficulties in measuring Paco2 after the administration ofacetazolamide (14, 15) . When an arterial sample is drawn, there is a relative excess of HCO . In the time required to measure Paco2, some of the HCO-converts to CO2 causing the measured Paco2 to be slightly high. Thus all the points on the experimental curve of Fig. 1 should probably be shifted slightly to the left. This would mean that slightly less of the CBF increase can probably be attributed to the increased Paco2 than our data actually predict. We plan to investigate the magnitude of this error in the future, but we do not expect it to be large.
Our data for the relationship between CBF and Paco2, both before and after acetazolamide administration (Fig. 1) is in good agreement with previous data, over the range of Paco2 studied (16, 17) .
In contrast to our findings, previous investigators (Table I) have reported up to 87% increases in CBF after acetazolamide administration, even when Paco2 has reportedly been controlled. Differences in species, level and type of anesthesia, and dose and time of administration of acetazolamide between these studies and ours make the discrepancy between our smaller CBF increase and those reported difficult to resolve. We would like to point out though, that some investigators used the brain a-v 02 content difference to estimate CBF. This technique is only valid if there is no change in cerebral oxygen metabolism (8) . Before our study, Posner and Plum (4) published the only data on the effect of acetazolamide on CMRO2. Other investigators, in turn, used their study to justify the use of brain a-v 02 content difference to estimate change in CBF because Posner and Plum reported no significant effect on CMRO2 by acetazolamide. However, their study used only five "normal" control patients, and of these one had previous brain damage and four had arteriosclerosis. Furthermore, these investigators did see a significant drop in CMRO2 in four patients with hepatic encephalopathy (4). We must conclude, therefore, that a failure to appreciate a significant drop in CMRO2 led many (Table I) to an overestimation of the CBF increase produced by the intravenous administration of acetazolamide.
Our study suggests that intravenous acetazolamide in healthy, lightly anesthetized rhesus monkeys produces a 32% reduction in CMRO2. This effect occurs within minutes of acetazolamide administration, which is consistent with the 3 min in vitro equilibration time between erythrocytic carbonic anhydrase and acetazolamide reported by Maren et al. (18) . Furthermore, these data suggest that the effect may, in fact, be primarily achieved through an effect of acetazolamide on the erythrocytic carbonic anhydrase, because it is unlikely that a significant amount ofthe drug can cross the bloodbrain barrier in this time. This is supported by the observation of Roth et al. (19) If the acetazolamide effect on CMRO2 is localized to the blood, what is its mechanism? As has been previously suggested by Cotev et al. (1) , carbonic anhydrase inhibition should interfere with the Bohr shift, the mechanism that augments 02 release from hemoglobin via an acidic pH shift (20) . Normally as the oxygencarrying erythrocytes enter the capillaries, CO2 diffuses in and is virtually instantaneously converted to H+ and HCO-by carbonic anhydrase. When the carbonic anhydrase is inhibited by acetazolamide (inhibition should be >99.99% at 30 mg/kg) (21), CO2 cannot convert to H+ and HCO before the blood has left the capillary, thus the Bohr shift does not occur and oxygen unloading is inhibited.
The hypothesis that inhibition of erythrocyte carbonic anhydrase with delayed hydration of carbon dioxide and prevention of the Bohr effect poses a significant limitation on oxygen delivery to brain is supported by two findings in our study. First, CMRO2 measured with hemolyzed blood was 9% higher than that measured with normal blood without any carbonic anhydrase inhibition (Fig. 5) .
Second, after acetazolamide was given, there was no significant difference between the CMRO2 measured with hemolyzed and normal blood. We believe these data can be interpreted in the following way. In the hemolyzed blood, carbon dioxide only had to cross the vascular endothelium to achieve immediate access to erythrocyte carbonic anhydrase which was free in plasma. Thus, the time course of the Bohr effect was speeded up and oxygen delivery to the tissue improved. After acetazolamide was given, the presence of carbonic anhydrase and hemoglobin free in the plasma made no difference because the enzyme was inhibited and, thus, once the CO2 crossed the capillary endothelium it still did not have enough time to be hydrated before it left the capillary. It must be emphasized that what is occurring is not due to a change in arterial hemoglobin saturation (which was always 100%), but to a change in the unloading of oxygen from hemoglobin. This phenomena could not be reproduced by altering inspired gas 02 content.
The increase in CMRO2 seen with hemolyzed blood without acetazolamide might easily be attributed to factor(s) other than carbonic anhydrase released by hemolysis from erythrocytes, leukocytes, and platelets. However, after acetazolamide was given, the CMRO2 was identical in both normal and hemolyzed blood and significantly depressed from the control level (Fig. 5) . It is well established that the only effect of acetazolamide is to inhibit carbonic anhydrase (22) . If some factor other than carbonic anhydrase released by hemolysis caused the increase in CMRO2, before acetazolamide, it should have caused a similar increase after acetazolamide, which did not occur. To confirm this, studies are currently underway in which bovine carbonic anhydrase is added to whole monkey blood. Preliminary results support those obtained with hemolyzed monkey blood.
An alternative explanation for this observation is that erythrocyte carbonic anhydrase, particularly isoenzyme B, may be more active when released into the extracellular fluid (i.e., plasma) environment by lysis (23), thus, actually speeding up the hydration of carbon dioxide. Neither this explanation nor the one we offer would be inconsistent with our hypothesis.
These data support the hypothesis that erythrocyte carbonic anhydrase is important for oxygen delivery to brain tissue. These observations are in accord with the critical nature of the temporal and spatial relationships existing in the microvasculature for erythrocyte carbonic anhydrase as previously emphasized by the work of Forster and Crandall (24) .
Actual measurements of cortical surface P02 after acetazolamide administration have shown an apparent increase in tissue Po2 and suggested (1, 3, 6, 7) that tissue oxygenation is quite adequate. We would point out, however, that tissue Po2 was measured using an oxygen electrode placed directly on the cortical surface. An electrode so placed would not only look at brain tissue P02, but also at the Po2 of any blood vessels near the electrode. There is a relatively higher concentration of veins and venules at the cortical surface, with arteries and arterioles tending to run deeper (25) . Thus the Po2 electrode would undoubtedly reflect the increased PVO2 caused by the delayed Bohr (26) (27) (28) (29) , tissue hypoxia sufficient to produce a 15% increase in CBF is not usually accompanied by a reduction in CMRO2. This suggests that the relationship between CMRO2, CBF, and tissue oxygen availability may be different under the circumstances of our experiment or, alternatively, that the factor(s) responsible for the flow increase we observe is not related to hypoxia. One important difference between our experiment and those of others concerns the means by which tissue hypoxia is achieved. As far as we have been able to determine, all reported experiments on the effect of hypoxia on CBF have been achieved by reducing the oxygen content of an inspired gas mixture. This stimulus not only reduces tissue Po2, but also directly reduces the oxygen tension of the vascular smooth muscle in parallel with the reduction in the arterial oxygen tension (Pao2). Because vascular smooth muscle is known to relax under the influence of hypoxia (30) , part of the increase in CBF in these studies might be mediated by a direct response of the smooth muscle to hypoxia. With intravenous acetazolamide, the Pao2 is not reduced, hence, a possible direct effect of hypoxia on the vascular smooth muscle may be averted. Changes in cerebrovascular resistance now must occur secondary to metabolic changes occurring within brain tissue. That such changes might have a less profound effect on cerebral circulation than previously appreciated should not be too surprising when it is realized that a substantial part of the blood flow resistance in the circulation of the cerebral cortex is not enclosed in the cerebral tissue (31, 32) . Thus, a large part of flow resistance cannot be adjusted acutely by a direct influence of metabolites on the vascular smooth muscle (31) (32) (33) .
It seems reasonable to suggest as a working hypothesis that acetazolamide may induce a critical reduction in tissue oxygen availability which is only partly compensated for by an increase in CBF. Further, the normal response of the cerebrovasculature to hypoxia is attenuated under these circumstances because the Po2 remains normal in the smooth muscle of a significant portion of the cerebral resistance vasculature. Further work is clearly needed in this area.
Finally, the possibility that acetazolamide may reduce CMRO2 by interfering with the oxygen unloading in the microvasculature must, if substantiated, be taken into consideration in the clinical use of the drug. Thus, its use in conditions such as epilepsy, where oxygen delivery to the tissue may at times become critical (33) , may need to be reconsidered.
